220 related articles for article (PubMed ID: 25004863)
1. Podocalyxin is a marker of poor prognosis in colorectal cancer.
Kaprio T; Fermér C; Hagström J; Mustonen H; Böckelman C; Nilsson O; Haglund C
BMC Cancer; 2014 Jul; 14():493. PubMed ID: 25004863
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
Larsson A; Johansson ME; Wangefjord S; Gaber A; Nodin B; Kucharzewska P; Welinder C; Belting M; Eberhard J; Johnsson A; Uhlén M; Jirström K
Br J Cancer; 2011 Aug; 105(5):666-72. PubMed ID: 21829192
[TBL] [Abstract][Full Text] [Related]
3. Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.
Larsson A; Fridberg M; Gaber A; Nodin B; Levéen P; Jönsson G; Uhlén M; Birgisson H; Jirström K
BMC Cancer; 2012 Jul; 12():282. PubMed ID: 22769594
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of two PODXL antibodies in 840 colorectal cancer patients.
Kaprio T; Hagström J; Fermér C; Mustonen H; Böckelman C; Nilsson O; Haglund C
BMC Cancer; 2014 Jul; 14():494. PubMed ID: 25004935
[TBL] [Abstract][Full Text] [Related]
5. Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer.
Larsson AH; Lehn S; Wangefjord S; Karnevi E; Kuteeva E; Sundström M; Nodin B; Uhlén M; Eberhard J; Birgisson H; Jirström K
J Transl Med; 2016 May; 14(1):128. PubMed ID: 27160084
[TBL] [Abstract][Full Text] [Related]
6. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin as a Prognostic Marker in Gastric Cancer.
Laitinen A; Böckelman C; Hagström J; Kokkola A; Fermér C; Nilsson O; Haglund C
PLoS One; 2015; 10(12):e0145079. PubMed ID: 26674770
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.
Heby M; Elebro J; Nodin B; Jirström K; Eberhard J
BMC Clin Pathol; 2015; 15():10. PubMed ID: 26028992
[TBL] [Abstract][Full Text] [Related]
9. Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases.
Larsson AH; Nodin B; Syk I; Palmquist I; Uhlén M; Eberhard J; Jirström K
Diagn Pathol; 2013 Jul; 8():109. PubMed ID: 23819542
[TBL] [Abstract][Full Text] [Related]
10. Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.
Boman K; Andersson G; Wennersten C; Nodin B; Ahlgren G; Jirström K
Biomark Res; 2017; 5():10. PubMed ID: 28293425
[TBL] [Abstract][Full Text] [Related]
11. Identification of LEA, a podocalyxin-like glycoprotein, as a predictor for the progression of colorectal cancer.
Yuan D; Chen H; Wang S; Liu F; Cheng Y; Fang J
Cancer Med; 2018 Oct; 7(10):5155-5166. PubMed ID: 30277651
[TBL] [Abstract][Full Text] [Related]
12. Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.
Boman K; Larsson AH; Segersten U; Kuteeva E; Johannesson H; Nodin B; Eberhard J; Uhlén M; Malmström PU; Jirström K
Br J Cancer; 2013 Jun; 108(11):2321-8. PubMed ID: 23652315
[TBL] [Abstract][Full Text] [Related]
13. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
[TBL] [Abstract][Full Text] [Related]
14. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
15. PODXL, negatively regulated by KLF4, promotes the EMT and metastasis and serves as a novel prognostic indicator of gastric cancer.
Zhang J; Zhu Z; Wu H; Yu Z; Rong Z; Luo Z; Xu Y; Huang K; Qiu Z; Huang C
Gastric Cancer; 2019 Jan; 22(1):48-59. PubMed ID: 29748877
[TBL] [Abstract][Full Text] [Related]
16. PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets.
He S; Du W; Li M; Yan M; Zheng F
BMC Cancer; 2020 Jul; 20(1):620. PubMed ID: 32615943
[TBL] [Abstract][Full Text] [Related]
17. Radiation-Induced Overexpression of TGFβ and PODXL Contributes to Colorectal Cancer Cell Radioresistance through Enhanced Motility.
Lee H; Kong JS; Lee SS; Kim A
Cells; 2021 Aug; 10(8):. PubMed ID: 34440856
[TBL] [Abstract][Full Text] [Related]
18. Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas.
Heby M; Karnevi E; Elebro J; Nodin B; Eberhard J; Saukkonen K; Hagström J; Mustonen H; Seppänen H; Haglund C; Jirström K; Larsson AH
Sci Rep; 2020 Jun; 10(1):10373. PubMed ID: 32587323
[TBL] [Abstract][Full Text] [Related]
19. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer.
Duncan TJ; Watson NF; Al-Attar AH; Scholefield JH; Durrant LG
World J Surg Oncol; 2007 Mar; 5():31. PubMed ID: 17349047
[TBL] [Abstract][Full Text] [Related]
20. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.
Nodin B; Johannesson H; Wangefjord S; O'Connor DP; Lindquist KE; Uhlén M; Jirström K; Eberhard J
Diagn Pathol; 2012 Aug; 7():115. PubMed ID: 22935204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
